Literature DB >> 2731185

Serological response of non-human primates to human melanoma disialoganglioside GD3.

G M Stuhlmiller1, K M Roberson, H F Seigler.   

Abstract

The immunogenicity of the disialoganglioside, GD3, a melanoma-tumor-associated antigen, has been evaluated in non-human primates. Sera from four chimpanzees and two monkeys were evaluated for anti-GD3 antibody activity by solid-phase radioimmunoassay using GD3 and control gangliosides as targets. Serum from one monkey, immunized with cells from a melanoma cell line, was strongly reactive with GD3, having a titer of greater than 2500. In contrast, serum from this animal was non-reactive with several other gangliosides including the structurally similar GM3. Anti-GD3 reactivity was also demonstrable, albeit in low titer, in the sera of an additional monkey and a chimpanzee. Each of these animals had likewise been immunized using cells from melanoma cell lines. On the basis of these observations, suggestive of a primate anti-GD3 antibody response, we initiated a series of immunizations of chimpanzee using purified GD3 bound to Salmonella minnesota, R595. IgG reactive with melanoma cells in the cell-binding assay was first detected in sera collected after 4 immunizations and increased in titer against each reactive melanoma cell line during the immunizations. Reactivity of this serum with melanoma cell lines demonstrated a direct correlation with the expression of GD3 by the respective cell line. Anti-GD3 reactivity was evident in solid-phase radioimmunoassay against purified GD3 beginning with serum collected after 11 immunizations. By comparison with its binding to the control ganglioside panel, this serum demonstrated strong specificity for GD3 (titer = 640) while having only marginal reactivity with GM3 (titer = 40). Immune serum from this animal was also able specifically to block subsequent binding of a murine IgM anti-GD3 antibody (DMab7) to target GD3 in solid-phase radioimmunoassay. Together, these observations suggest that GD3, in the form of a purified molecule bound to a bacterial matrix or as part of the intact melanoma cell membrane, can be immunogenic in non-human primates, and is able to elicit an antibody response of appropriate specificity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2731185     DOI: 10.1007/bf00199997

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  22 in total

1.  The use of non-human primates for production of antisera to human tumor-associated antigens.

Authors:  G M Stuhlmiller; T Mohanakumar; R S Metzgar; H F Seigler
Journal:  J Immunol Methods       Date:  1976       Impact factor: 2.303

2.  Expression of human fetal brain antigens by human tumors of neuroectodermal origin as defined by monoclonal antibodies.

Authors:  C J Wikstrand; D D Bigner
Journal:  Cancer Res       Date:  1982-01       Impact factor: 12.701

3.  Concentration, composition and structure of gangliosides from the central nervous systems of dogfish, Squalus acanthia, and cod, Gadus callarias.

Authors:  P Fredman; R Norén; J E Månsson; L Svennerholm
Journal:  Biochim Biophys Acta       Date:  1982-11-12

4.  Specific active immunotherapy for melanoma.

Authors:  H F Seigler; E Cox; F Mutzner; L Shepherd; E Nicholson; W W Shingleton
Journal:  Ann Surg       Date:  1979-09       Impact factor: 12.969

5.  Review of melanoma antigens recognized by monoclonal antibodies (MAbs). Their functional significance and applications in diagnosis and treatment of melanoma.

Authors:  P Hersey
Journal:  Pathology       Date:  1985-04       Impact factor: 5.306

6.  Disialoganglioside GD3 on human melanoma serves as a relevant target antigen for monoclonal antibody-mediated tumor cytolysis.

Authors:  D A Cheresh; C J Honsik; L K Staffileno; G Jung; R A Reisfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

7.  Inhibition of human melanoma cell growth in vitro by monoclonal anti-GD3-ganglioside antibody.

Authors:  W G Dippold; A Knuth; K H Meyer zum Büschenfelde
Journal:  Cancer Res       Date:  1984-02       Impact factor: 12.701

8.  Melanoma patient antibody responses to melanoma tumor-associated antigens defined by murine monoclonal antibodies.

Authors:  H F Seigler; M K Wallack; C E Vervaert; J A Bash; K M Roberson; G M Stuhlmiller
Journal:  J Biol Response Mod       Date:  1989-02

9.  Cell surface antigens of human malignant melanoma: definition of six antigenic systems with mouse monoclonal antibodies.

Authors:  W G Dippold; K O Lloyd; L T Li; H Ikeda; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1980-10       Impact factor: 11.205

10.  Antibody-induced release of cellular proteinases: loss of adhesion of human melanoma cells after binding of anti-melanoma antibody.

Authors:  K H Singer; K Hashimoto; G M Stuhlmiller; G S Lazarus
Journal:  J Immunol       Date:  1982-03       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.